VHPKQHR Peptide Modified Ultrasmall Paramagnetic Iron Oxide Nanoparticles Targeting Rheumatoid Arthritis for T1-Weighted Magnetic Resonance Imaging

Chunyu Zhang, Wentao Huang, Chen Huang, Chengqian Zhou, Yukuan Tang, Wei Wei, Yongsheng Li, Yu Luo, Quan Zhou, Wenli ChenFrontiers in Bioengineering and Biotechnology 2022 · DOI

TL;DR

Researchers have developed a novel contrast agent, UVHP, by modifying ultrasmall paramagnetic iron oxide nanoparticles (USPIO) with a peptide that targets VCAM-1, a marker for rheumatoid arthritis (RA). This targeted agent shows promise for early RA diagnosis via T1-weighted MRI, demonstrating enhanced signal in affected joints in animal models with low toxicity.

What Problem Does This Paper Address?

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting millions globally, and early diagnosis is crucial for effective treatment and mitigating joint damage. While MRI is a powerful imaging tool for RA, current contrast agents often lack specificity, leading to potential missed diagnoses or delayed treatment. The paper addresses the need for a targeted contrast agent that can specifically identify early signs of RA, particularly focusing on the overexpression of Vascular Cell Adhesion Molecule-1 (VCAM-1) in inflamed synovial tissues, a known hallmark of RA.

Methods

The core of this research lies in the synthesis and characterization of a novel contrast agent, UVHP. This involved:

  • USPIO Synthesis: Ultrasmall paramagnetic iron oxide nanoparticles (USPIO) were synthesized using a standard chemical co-precipitation method.
  • Peptide Conjugation: The VHPKQHR peptide, known for its high affinity to VCAM-1, was chemically conjugated to the surface of USPIO using carbodiimide chemistry (EDC/NHS coupling). This process created the UVHP nanoparticles.
  • Characterization: The synthesized USPIO and UVHP were thoroughly characterized using:
  • Transmission Electron Microscopy (TEM) for size and morphology.
  • Dynamic Light Scattering (DLS) for hydrodynamic size.
  • Zeta potential measurements to assess surface charge and stability.
  • Thermogravimetric Analysis (TGA) to confirm peptide conjugation.
  • Fourier Transform Infrared (FTIR) spectroscopy to identify functional groups and confirm peptide attachment.
  • Relaxivity measurements (r1 and r2) using a clinical MRI scanner to evaluate their potential as MRI contrast agents.
  • In Vitro Studies:
    • Cell Culture: Mouse aortic endothelial cells (MAECs), RAW264.7 cells, and human fibroblast-like synoviocyte RA (HFLS-RA) cells were used.
  • VCAM-1 Expression: MAECs were stimulated with TNF-α to induce VCAM-1 overexpression, mimicking inflammatory conditions in RA.
  • Cellular Uptake: The uptake of UVHP by cells, particularly those with induced VCAM-1 expression, was quantified using Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) to measure iron content.
  • Cytotoxicity Assays: Hemolytic assays and Cell Counting Kit-8 (CCK-8) assays were performed to evaluate the safety and biocompatibility of UVHP.
  • Cellular MRI: T1-weighted MRI was used to assess the signal enhancement in cells treated with USPIO and UVHP, both with and without TNF-α stimulation.
  • In Vivo Studies:
    • RA Mouse Model: A collagen-induced arthritis (CIA) model was established in C57BL/6 mice.
  • In Vivo MRI: T1-weighted MRI was performed on the knee joints of RA model mice and control mice after injection of USPIO or UVHP to assess targeting efficacy.
  • Biodistribution: The distribution of iron from injected USPIO and UVHP in various organs was analyzed using ICP-OES.
  • Histopathology: H&E staining of knee joint sections and major organs was conducted to evaluate the pathological changes and safety of UVHP.

Datasets

Not discussed in the paper. The study relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • Targeted Contrast Agent Design: The successful conjugation of the VHPKQHR peptide to USPIO creates a "smart" contrast agent (UVHP) that specifically seeks out VCAM-1, a key marker in RA inflammation. This moves beyond non-specific contrast agents.
  • VCAM-1 as a Viable Target: The study confirms that VCAM-1 is indeed upregulated in inflammatory conditions relevant to RA (induced in MAECs) and that UVHP effectively targets these cells.
  • Early Detection Potential: The ability of UVHP to enhance T1-weighted MRI signals in the joints of RA model mice, even before significant gross pathology might be apparent, suggests its utility for early diagnosis.
  • Dual-Mode Imaging Potential (Speculative): While primarily focused on T1-weighted imaging, the paper notes that USPIO and UVHP aggregation could potentially lead to T2-weighted MRI signal changes, hinting at future possibilities for dual-mode imaging.
  • Safety Profile: The demonstrated low toxicity and good hemocompatibility of UVHP are critical for its potential clinical translation, especially compared to some existing contrast agents.

Key Results

  • UVHP Characterization: UVHP nanoparticles had a mean diameter of 6.7 nm, a zeta potential of -27.7 mV, and an r2/r1 value of 1.73, indicating suitability for T1-weighted MRI.
  • Cellular Targeting: TNF-α stimulation significantly increased VCAM-1 expression in MAECs. UVHP uptake by these stimulated cells was substantially higher (17-fold increase at 200 µg/mL Fe concentration) compared to non-stimulated cells.
  • In Vitro MRI: UVHP showed significantly higher T1-weighted MRI signal enhancement in TNF-α-stimulated MAECs and HFLS-RA cells compared to USPIO, confirming VCAM-1 targeting.
  • In Vivo MRI: In RA model mice, UVHP injection led to a significant increase in T1-weighted MRI signal intensity in the knee joints compared to control mice and mice injected with non-targeted USPIO.
  • Safety: Hemolysis was below 5% across tested UVHP concentrations, and cell viability remained above 80% even at high UVHP concentrations (200 µg/mL Fe). Histological analysis of major organs in RA mice after UVHP injection showed no significant changes.

Limitations and Future Work

  • Animal Model Specificity: While the RA mouse model is valuable, further validation in other RA models and eventually human studies is necessary.
  • Biodistribution Nuances: While UVHP showed targeting to RA joints, a significant portion was also found in the spleen and liver, common for nanoparticles. Further research is needed to optimize distribution and minimize off-target accumulation.
  • Long-Term Effects: The study primarily focused on short-term effects. Long-term safety and efficacy studies would be beneficial.
  • Clinical Translation: Bridging the gap from animal studies to human clinical trials requires extensive further research, including pharmacokinetic studies and dose optimization.
  • Dual-Mode Imaging Exploration: The paper suggests exploring the potential of UVHP for both T1 and T2 weighted MRI, which could offer more comprehensive diagnostic information.

Summary updated

Abstract

Magnetic resonance imaging (MRI) could be the ideal diagnostic modality for early rheumatoid arthritis (RA). Vascular cell adhesion molecule-1 (VCAM-1) is highly expressed in synovial locations in patients with RA, which could be a potential target protein for RA diagnosis. The peptide VHPKQHR (VHP) has a high affinity to VCAM-1. To make the contrast agent to target RA at an early stage, we used VHP and ultrasmall paramagnetic iron oxide (USPIO) to synthesize UVHP (U stands for USPIO) through a chemical reaction with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide. The size of UVHP was 6.7 nm; the potential was -27.7 mV, and the <i>r</i> <sub>2</sub>/<i>r</i> <sub>1</sub> value was 1.73. Cytotoxicity assay exhibited that the cell survival rate was higher than 80% at even high concentrations of UVHP (Fe concentration 200 µg/mL), which showed the UVHP has low toxicity. Compared with no TNF-α stimulation, VCAM-1 expression was increased nearly 3-fold when mouse aortic endothelial cells (MAECs) were stimulated with 50 ng/mL TNF-α; cellular Fe uptake was increased very significantly with increasing UVHP concentration under TNF-α treatment; cellular Fe content was 17 times higher under UVHP with Fe concentration 200 µg/mL treating MAECs. These results indicate that UVHP can target overexpression of VCAM-1 at the cellular level. RA mice models were constructed with adjuvant-induced arthritis. <i>In vivo</i> MRI and biodistribution results show that the signal intensity of knee joints was increased significantly and Fe accumulation in RA model mice compared with normal wild-type mice after injecting UVHP 24 h. These results suggest that we have synthesized a simple, low-cost, and less toxic contrast agent UVHP, which targeted VCAM-1 for early-stage RA diagnosis and generates high contrast in T<sub>1</sub>-weighted MRI.
BibTeX
@inproceedings{zhang2022vhpkqhr,
  author = {Chunyu Zhang and Wentao Huang and Chen Huang and Chengqian Zhou and Yukuan Tang and Wei Wei and Yongsheng Li and Yukuan Tang and Yu Luo and Quan Zhou and Wenli Chen and Quan Zhou and Wenli Chen},
  title = {{VHPKQHR Peptide Modified Ultrasmall Paramagnetic Iron Oxide Nanoparticles Targeting Rheumatoid Arthritis for T1-Weighted Magnetic Resonance Imaging}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2022},
  doi = {10.3389/fbioe.2022.821256},
}
Figure